The short answer
Ghrelin is secreted by the stomach and is the only known circulating hormone that stimulates feeding. LEAP2, identified in 2017 as an endogenous antagonist of the ghrelin receptor, fully blocks that activation, and its secretion is suppressed by fasting, the mirror image of ghrelin's.
Key facts
- Ghrelin source
- Stomach
- Receptor
- GHSR, the growth hormone secretagogue receptor
- Direction of effect
- Stimulates feeding (orexigenic)
- Downstream neurons
- NPY and AgRP neurons
- LEAP2 full name
- Liver-expressed antimicrobial peptide 2
- LEAP2 sources
- Liver and small intestine
- LEAP2 during fasting
- Secretion suppressed
- LEAP2 identified as GHSR antagonist
- 2017 (Ge X et al., Cell Metab 2018)
Why ghrelin is structurally unusual
Almost every circulating gut hormone that reaches the appetite circuitry reduces feeding: GLP-1, PYY, cholecystokinin, amylin, GDF15. Ghrelin goes the other way. Nakazato and colleagues showed that intracerebroventricular ghrelin strongly stimulated feeding in rats and increased body weight gain, and that anti-ghrelin immunoglobulin robustly suppressed feeding, so the endogenous hormone is doing this too, not just the injected one. It also increased feeding in rats genetically deficient in growth hormone, which matters because ghrelin's receptor was originally characterised as a growth hormone secretagogue receptor. The feeding effect is not downstream of growth hormone; it is its own action.
The circuit it runs through
After central ghrelin administration, Fos protein appeared in the regions that matter most for feeding, including NPY and AgRP neurons, the same arcuate population that PYY(3-36) silences from the other direction. Antibodies and antagonists of NPY and AgRP abolished ghrelin-induced feeding, so those neurons are not merely activated but required. Ghrelin also augmented NPY gene expression and blocked leptin-induced reduction in feeding, which the authors describe as a competitive interaction between the two hormones. Two signals, one reporting stored energy and one reporting an empty stomach, converge on the same neurons with opposite effects.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
The antagonist nobody was looking for
How ghrelin action is regulated remained poorly understood for years after the hormone itself was well described. Ge and colleagues reported the answer in 2017: liver-expressed antimicrobial peptide 2, a molecule named for an entirely different presumed function, is an endogenous antagonist of GHSR. It is produced in the liver and small intestine, it fully inhibits GHSR activation by ghrelin, and it blocks ghrelin's major effects in vivo: food intake, growth hormone release, and the maintenance of viable glucose levels during chronic caloric restriction. Neutralising antibodies against endogenous LEAP2 do the reverse and enhance ghrelin action.
Why the fasting behaviour is the elegant part
LEAP2 secretion is suppressed by fasting. Ghrelin rises with fasting. The two move in opposite directions on the same stimulus, so the tone at the receptor is set by a ratio rather than by either concentration alone. The agonist climbs while the antagonist withdraws, and both changes push the same way. A system regulated by opposing ligands on a single receptor has a wider dynamic range than one regulated by agonist concentration alone, and it can be tuned from two places. The authors describe this as a mechanism for fine-tuning ghrelin action in response to changing environmental conditions.
Why blocking hunger has not produced a drug
Ghrelin looks like an obvious target: it is the one signal telling the brain to eat, so blocking it should reduce eating. Ghrelin antagonists and vaccines have been pursued for two decades without producing a licensed weight-management medicine. Part of the reason is redundancy: removing one orexigenic signal leaves the rest of a system evolved to defend against energy deficit, which compensates. Part of it is that GHSR does several other things, including a role in maintaining glucose during prolonged caloric restriction that the LEAP2 work makes explicit. Blocking a receptor whose job includes preventing hypoglycaemia during starvation is not a free action.
The connection to growth hormone secretagogues
GHSR is the receptor that growth hormone secretagogues engage, which is why this pathway appears twice in this library from opposite directions. Compounds developed to stimulate that receptor for growth hormone release are engaging the same receptor LEAP2 evolved to block, and are therefore engaging a system that also drives feeding and defends glucose. Anyone reading about GHSR agonism should know that the receptor's endogenous regulation includes a dedicated antagonist, and that its physiology extends well beyond growth hormone. Nothing supplied on this site is a licensed medicine and none of this is guidance about any compound.
Frequently asked questions
Does ghrelin rise before meals?
Ghrelin's relationship with fasting and feeding is well established, and the LEAP2 work adds that its antagonist moves the opposite way when food is withheld. The practically important point is that the receptor's activation state depends on both ligands, so measuring ghrelin alone gives an incomplete picture.
Why is an antimicrobial peptide regulating appetite?
The name reflects the context in which LEAP2 was first described, not the full range of what it does. Proteins are routinely named for whichever activity was noticed first, and a molecule doing two unrelated jobs is common rather than surprising.
Would blocking ghrelin cause weight loss?
It has not been shown to in any licensed product, despite sustained effort. Redundancy in the systems defending against energy deficit is the usual explanation, and the receptor's other roles complicate blocking it.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedNakazato M et al., A role for ghrelin in the central regulation of feeding - Nature 2001 (PMID 11196643)pubmed.ncbi.nlm.nih.gov
- PubMedGe X et al., LEAP2 Is an Endogenous Antagonist of the Ghrelin Receptor - Cell Metab 2018 (PMID 29233536)pubmed.ncbi.nlm.nih.gov
- PubMedHalaas JL et al., Weight-reducing effects of the plasma protein encoded by the obese gene - Science 1995 (PMID 7624777)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- There Is No Amylin Receptor GeneThe amylin receptor is not its own protein. It is the calcitonin receptor plus an accessory protein, and which accessory decides what the receptor recognises.
- Four Hormones, One Failure ModeLeptin, PYY, ghrelin and GDF15 all reduce or drive food intake in animals. None of them produced a weight-management drug, and the reasons they failed rhyme.
- Why the Same Gene Makes Glucagon in One Cell and GLP-1 in AnotherGlucagon, GLP-1, GLP-2, oxyntomodulin and glicentin all come from a single precursor. The textbook explanation of how a cell chooses between them is incomplete.
- The Other Peptide the L Cell ReleasesGLP-2 is co-secreted with GLP-1 from the very same cells and does something entirely different. Its analogue teduglutide is a licensed prescription medicine.
- A Risk Ratio of 0.57 That Means Almost NothingOne meta-analysis reported RR 0.568 for suicidality with GLP-1 drugs. Its interval ran from 0.077 to 4.205, which is compatible with almost any answer.